文献速递胸部肿瘤

波齐替尼治疗携带HER2外显子20突变的初治非小细胞肺癌:ZENITH20-4多中心多队列开放标签2期试验(第4队列)

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
PubMed 文献 · J Thorac Oncol · 2023-03-21

ZENITH20-C4研究评估波齐替尼16 mg每日一次或8 mg每日两次治疗携带HER2外显子20插入突变的初治NSCLC患者。80例患者客观缓解率为39%(95%CI 28%-50%),疾病控制率73%,中位缓解持续时间5.7个月,中位无进展生存期5.6个月。常见3级治疗相关不良事件为皮疹、口腔炎和腹泻。

要点

  • 初治HER2外显子20插入突变NSCLC患者接受波齐替尼的客观缓解率为39%,疾病控制率为73%。
  • 中位缓解持续时间为5.7个月,中位无进展生存期为5.6个月。
  • 常见3级治疗相关不良事件为皮疹、口腔炎和腹泻。

核心结论

  • 波齐替尼在携带HER2外显子20突变的初治NSCLC患者中显示出有临床意义的疗效且毒性可控。

研究设计与样本

  • ZENITH20是一项开放标签、多队列、多中心、全球性2期试验,ZENITH20-C4队列纳入携带HER2外显子20插入突变的初治NSCLC患者,波齐替尼给药方案为16 mg每日一次或8 mg每日两次。
  • 共80例患者接受治疗(16 mg每日一次组47例,8 mg每日两次组33例)。

主要发现

  • 客观缓解率为39%(95%CI 28%-50%;80例中31例),疾病控制率为73%(95%CI 61%-82%;80例中58例),80%的患者出现肿瘤缩小。
  • 中位缓解持续时间为5.7个月(95%CI 4.6-11.9),中位无进展生存期为5.6个月(95%CI 5.4-7.3)。
  • 常见3级治疗相关不良事件:皮疹(每日一次组45%,每日两次组39%)、口腔炎(每日一次组21%,每日两次组15%)、腹泻(每日一次组15%,每日两次组21%)。
  • 在所有HER2外显子20插入突变亚型中,7例(9%)携带G778_P780dupGSP突变的肿瘤患者临床结局最佳(客观缓解率71%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: ERBB2 or HER2 alterations are found in approximately 2% to 5% of NSCLCs; most are exon 20 insertion mutations. The efficacy and safety of poziotinib, an oral tyrosine kinase inhibitor, were assessed in patients with treatment-naive NSCLC whose tumors harbor HER2 exon 20 insertions. METHODS: ZENITH20 is an open-label, multicohort, multicenter, global, phase 2 trial. ZENITH20-C4 enrolled treatment-naive patients with NSCLC with tumors harboring HER2 exon 20 insertions. Poziotinib was administered 16 mg once daily (QD) or 8 mg twice daily (BID). The primary end point was objective response rate (ORR) by independent central review. Secondary and exploratory end points included disease control rate, duration of response, progression-free survival, and safety. RESULTS: A total of 80 patients (16 mg QD, n = 47; 8 mg BID, n = 33) were treated in ZENITH20-C4. ORR was 39% (95% confidence interval [CI]: 28%-50%; 31 of 80), with a disease control rate of 73% (95% CI: 61%-82%; 58 of 80); 80% of the patients experienced tumor reduction. Median duration of response was 5.7 (95% CI: 4.6-11.9) months, and median progression-free survival was 5.6 (95% CI: 5.4-7.3) months. The most common grade 3 treatment-related adverse events were rash (QD, 45%; BID, 39%), stomatitis (QD, 21%; BID, 15%), and diarrhea (QD, 15%; BID, 21%). Among all subtypes of HER2 exon 20 insertions, seven patients (9%) harboring tumors with G778_P780dupGSP had the best clinical outcomes (ORR, 71%). CONCLUSIONS: Poziotinib was found to have clinically meaningful efficacy with a manageable toxicity profile for patients with treatment-naive NSCLC harboring HER2 exon 20 mutations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Cornelissen R, Prelaj A, Sun S, et al. Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). J Thorac Oncol. 2023. PMID: 36958688. doi:10.1016/j.jtho.2023.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。